Annual EBITDA:
$9.21M+$13.10M(+336.52%)Summary
- As of today, CDXC annual EBITDA is $9.21 million, with the most recent change of +$13.10 million (+336.52%) on December 31, 2024.
- During the last 3 years, CDXC annual EBITDA has risen by +$34.66 million (+136.19%).
Performance
CDXC EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Range
Earnings dates
Quarterly EBITDA:
$5.14M-$2.33M(-31.18%)Summary
- As of today, CDXC quarterly EBITDA is $5.14 million, with the most recent change of -$2.33 million (-31.18%) on March 31, 2025.
- Over the past year, CDXC quarterly EBITDA has increased by +$5.48 million (+1607.33%).
Performance
CDXC Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Range
Earnings dates
TTM EBITDA:
$14.69M+$5.48M(+59.51%)Summary
- As of today, CDXC TTM EBITDA is $14.69 million, with the most recent change of +$5.48 million (+59.51%) on March 31, 2025.
- Over the past year, CDXC TTM EBITDA has increased by +$17.40 million (+642.70%).
Performance
CDXC TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
CDXC EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | +336.5% | +1607.3% | +642.7% |
| 3Y3 Years | +136.2% | +171.6% | +157.2% |
| 5Y5 Years | +130.9% | +193.1% | +169.4% |
CDXC EBITDA Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | at high | +136.2% | -31.2% | +296.5% | at high | +171.0% |
| 5Y | 5-Year | at high | +130.9% | -31.2% | +161.0% | at high | +155.5% |
| All-Time | All-Time | at high | +128.5% | -31.2% | +159.7% | at high | +144.6% |
CDXC EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | $5.14M(-31.2%) | $14.69M(+59.5%) |
| Dec 2024 | $9.21M(+336.5%) | $7.47M(+279.5%) | $9.21M(+373.3%) |
| Sep 2024 | - | $1.97M(+1626.3%) | $1.95M(+369.9%) |
| Jun 2024 | - | $114.00K(+133.4%) | -$721.00K(+73.4%) |
| Mar 2024 | - | -$341.00K(-266.3%) | -$2.71M(+30.5%) |
| Dec 2023 | -$3.89M(+76.7%) | $205.00K(+129.3%) | -$3.89M(+23.5%) |
| Sep 2023 | - | -$699.00K(+62.7%) | -$5.09M(+27.4%) |
| Jun 2023 | - | -$1.87M(-22.5%) | -$7.00M(+36.8%) |
| Mar 2023 | - | -$1.53M(-54.5%) | -$11.09M(+33.8%) |
| Dec 2022 | -$16.74M(+34.2%) | -$989.00K(+62.2%) | -$16.74M(+19.0%) |
| Sep 2022 | - | -$2.62M(+56.1%) | -$20.68M(+21.9%) |
| Jun 2022 | - | -$5.96M(+17.1%) | -$26.49M(-3.2%) |
| Mar 2022 | - | -$7.18M(-45.8%) | -$25.68M(-0.9%) |
| Dec 2021 | -$25.45M(-38.7%) | -$4.93M(+41.5%) | -$25.45M(+2.9%) |
| Sep 2021 | - | -$8.43M(-63.9%) | -$26.20M(-21.3%) |
| Jun 2021 | - | -$5.14M(+26.1%) | -$21.60M(-9.2%) |
| Mar 2021 | - | -$6.96M(-22.3%) | -$19.77M(-7.8%) |
| Dec 2020 | -$18.34M(+38.4%) | -$5.69M(-48.9%) | -$18.34M(+13.3%) |
| Sep 2020 | - | -$3.82M(-15.2%) | -$21.16M(+11.2%) |
| Jun 2020 | - | -$3.31M(+40.0%) | -$23.82M(+12.7%) |
| Mar 2020 | - | -$5.52M(+35.1%) | -$27.30M(+8.3%) |
| Dec 2019 | -$29.78M(+7.9%) | -$8.50M(-31.1%) | -$29.78M(-1.7%) |
| Sep 2019 | - | -$6.49M(+4.4%) | -$29.28M(+6.0%) |
| Jun 2019 | - | -$6.79M(+15.2%) | -$31.16M(+2.9%) |
| Mar 2019 | - | -$8.00M(+0.1%) | -$32.11M(+0.7%) |
| Dec 2018 | -$32.33M(-106.4%) | -$8.01M(+4.3%) | -$32.33M(+1.8%) |
| Sep 2018 | - | -$8.37M(-8.2%) | -$32.93M(-19.5%) |
| Jun 2018 | - | -$7.73M(+5.9%) | -$27.55M(-23.7%) |
| Mar 2018 | - | -$8.22M(+4.5%) | -$22.26M(-42.1%) |
| Dec 2017 | -$15.66M(-530.0%) | -$8.61M(-188.2%) | -$15.66M(-72.0%) |
| Sep 2017 | - | -$2.99M(-21.9%) | -$9.10M(-31.1%) |
| Jun 2017 | - | -$2.45M(-51.2%) | -$6.94M(-72.8%) |
| Mar 2017 | - | -$1.62M(+21.0%) | -$4.02M(-117.2%) |
| Dec 2016 | -$2.49M | -$2.05M(-148.7%) | -$1.85M(-113.3%) |
| Sep 2016 | - | -$824.40K(-273.5%) | -$867.50K(-495.8%) |
| Jun 2016 | - | $475.10K(-13.4%) | $219.20K(+161.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2016 | - | $548.70K(+151.4%) | -$358.50K(+79.3%) |
| Dec 2015 | -$1.74M(+65.1%) | -$1.07M(-506.7%) | -$1.74M(-2.1%) |
| Sep 2015 | - | $262.30K(+355.7%) | -$1.70M(+33.2%) |
| Jun 2015 | - | -$102.60K(+87.6%) | -$2.55M(+36.7%) |
| Mar 2015 | - | -$828.30K(+19.7%) | -$4.02M(+19.1%) |
| Dec 2014 | -$4.97M(-20.8%) | -$1.03M(-76.8%) | -$4.97M(-8.3%) |
| Sep 2014 | - | -$583.20K(+63.0%) | -$4.59M(+11.5%) |
| Jun 2014 | - | -$1.58M(+11.4%) | -$5.19M(-13.7%) |
| Mar 2014 | - | -$1.78M(-174.1%) | -$4.56M(-10.9%) |
| Dec 2013 | -$4.12M(+63.5%) | -$649.30K(+45.1%) | -$4.12M(+18.9%) |
| Sep 2013 | - | -$1.18M(-24.2%) | -$5.07M(+4.9%) |
| Jun 2013 | - | -$952.00K(+28.5%) | -$5.34M(+35.6%) |
| Mar 2013 | - | -$1.33M(+17.1%) | -$8.29M(+26.6%) |
| Dec 2012 | -$11.29M(-51.3%) | -$1.61M(-11.1%) | -$11.29M(+6.5%) |
| Sep 2012 | - | -$1.45M(+62.9%) | -$12.07M(+6.6%) |
| Jun 2012 | - | -$3.90M(+10.0%) | -$12.92M(-20.2%) |
| Mar 2012 | - | -$4.33M(-81.6%) | -$10.75M(-44.0%) |
| Dec 2011 | -$7.46M(-358.0%) | -$2.39M(-3.9%) | -$7.46M(-27.2%) |
| Sep 2011 | - | -$2.30M(-32.6%) | -$5.87M(-35.1%) |
| Jun 2011 | - | -$1.73M(-65.4%) | -$4.34M(-54.6%) |
| Mar 2011 | - | -$1.05M(-32.6%) | -$2.81M(-72.4%) |
| Dec 2010 | -$1.63M(-227.1%) | -$790.00K(-2.0%) | -$1.63M(-91.2%) |
| Sep 2010 | - | -$774.20K(-292.4%) | -$852.40K(-450.6%) |
| Jun 2010 | - | -$197.30K(-249.7%) | -$154.80K(-6.7%) |
| Mar 2010 | - | $131.80K(+1137.8%) | -$145.10K(+70.9%) |
| Dec 2009 | -$498.20K(+70.5%) | -$12.70K(+83.4%) | -$498.20K(+50.6%) |
| Sep 2009 | - | -$76.60K(+59.2%) | -$1.01M(+34.3%) |
| Jun 2009 | - | -$187.60K(+15.2%) | -$1.54M(+22.2%) |
| Mar 2009 | - | -$221.30K(+57.7%) | -$1.97M(-12.4%) |
| Dec 2008 | -$1.69M(-4295.1%) | -$523.30K(+13.3%) | -$1.76M(-42.5%) |
| Sep 2008 | - | -$603.40K(+3.6%) | -$1.23M(-93.5%) |
| Jun 2008 | - | -$626.00K(>-9900.0%) | -$636.70K(-4581.6%) |
| Feb 2008 | - | -$2900.00(+17.1%) | -$13.60K(+41.6%) |
| Nov 2007 | -$38.40K | -$3500.00(+18.6%) | -$23.30K(-17.7%) |
| Aug 2007 | - | -$4300.00(-48.3%) | -$19.80K(-27.7%) |
| May 2007 | - | -$2900.00(+77.0%) | -$15.50K(-23.0%) |
| Feb 2007 | - | -$12.60K | -$12.60K |
FAQ
- What is Niagen Bioscience, Inc. annual EBITDA?
- What is the all-time high annual EBITDA for Niagen Bioscience, Inc.?
- What is Niagen Bioscience, Inc. annual EBITDA year-on-year change?
- What is Niagen Bioscience, Inc. quarterly EBITDA?
- What is the all-time high quarterly EBITDA for Niagen Bioscience, Inc.?
- What is Niagen Bioscience, Inc. quarterly EBITDA year-on-year change?
- What is Niagen Bioscience, Inc. TTM EBITDA?
- What is the all-time high TTM EBITDA for Niagen Bioscience, Inc.?
- What is Niagen Bioscience, Inc. TTM EBITDA year-on-year change?
What is Niagen Bioscience, Inc. annual EBITDA?
The current annual EBITDA of CDXC is $9.21M
What is the all-time high annual EBITDA for Niagen Bioscience, Inc.?
Niagen Bioscience, Inc. all-time high annual EBITDA is $9.21M
What is Niagen Bioscience, Inc. annual EBITDA year-on-year change?
Over the past year, CDXC annual EBITDA has changed by +$13.10M (+336.52%)
What is Niagen Bioscience, Inc. quarterly EBITDA?
The current quarterly EBITDA of CDXC is $5.14M
What is the all-time high quarterly EBITDA for Niagen Bioscience, Inc.?
Niagen Bioscience, Inc. all-time high quarterly EBITDA is $7.47M
What is Niagen Bioscience, Inc. quarterly EBITDA year-on-year change?
Over the past year, CDXC quarterly EBITDA has changed by +$5.48M (+1607.33%)
What is Niagen Bioscience, Inc. TTM EBITDA?
The current TTM EBITDA of CDXC is $14.69M
What is the all-time high TTM EBITDA for Niagen Bioscience, Inc.?
Niagen Bioscience, Inc. all-time high TTM EBITDA is $14.69M
What is Niagen Bioscience, Inc. TTM EBITDA year-on-year change?
Over the past year, CDXC TTM EBITDA has changed by +$17.40M (+642.70%)